Clinical Trial

Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant)

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Healthcare claims database study to provide safety information on maternal, fetal and infant outcomes among women exposed to QUVIVIQ (daridorexant) during pregnancy
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-04-26; most recent amendment 2025-08-18.
Trial Details
NCT Number NCT06393504
Lead Sponsor Idorsia Pharmaceuticals Ltd.
Collaborators: Carelon Research
Conditions Insomnia Disorder
Enrollment 2,095 participants
Start Date 2023-11-30
Primary Completion 2028-04 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2025-08-19